A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Study identifier:D7700C00001

ClinicalTrials.gov identifier:NCT06311760

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, And Pharmacokinetics of AZD0292 Following Single Ascending Dose Administration to Healthy Participants

Medical condition

Healthy Participants Study

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD0292, Placebo

Sex

All

Actual Enrollment

32

Study type

Interventional

Age

18 Years - 60 Years

Date

Study Start Date: 09 Apr 2024
Estimated Primary Completion Date: 04 Nov 2024
Estimated Study Completion Date: 04 Nov 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria